A CLINICAL TRIAL WAS CARRIED OUT IN Children’s Ward at G.T Hospital, Bombay to study the role of “AEKNIL” as an antipyretic. 

For control studies, other antipyretics viz., A.P.C Powder and ‘Mist Diaphoretic” were used. Three hundred and sixty cases were studies over a period of one year. The cases were divided into three groups as follows: 

Group 1         included 120 cases treated with “AEKNIL”

Group 2         included 120 cases treated with “A.P.C”

Group 3         included 120 cases treated with “Mist Diaphoretic”

The main aim of the trial was to study the effect of “AEKNIL” in controlling the pyrexia irrespective of its aetiology. It was used only for symptomatic relief. Specific treatment with antibiotics etc, was given as required. 

Pharmacology of “AEKNIL” 

It contains N-Acetyl Para Aminophenol (Paracetamol B.P). Its primary action is believed to be a central one, affecting the hypothalamus and thalamus, giving rise to “Analgesic-Antipyretic effects”. Heat dissipation is apparently increased by mobilising water, dilating cutaneous blood vessels and increasing perspiration. Its analgesic action is manifested by raising the pain threshold at the level of thalamus. Absorption takes place rapidly after oral administration and peak levels are reached in about 1 to 2 hours following administration. 

“AEKNIL” is available in both Oral and Injectable forms.

Each ml. contains